The estimated Net Worth of Alan L Rubino is at least $1.28 Миллион dollars as of 1 May 2024. Mr. Rubino owns over 3,200 units of Vericel Corp stock worth over $1,039,798 and over the last 10 years he sold VCEL stock worth over $0. In addition, he makes $237,585 as Independent Director at Vericel Corp.
Alan has made over 9 trades of the Vericel Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,200 units of VCEL stock worth $139,840 on 1 May 2024.
The largest trade he's ever made was exercising 5,000 units of Vericel Corp stock on 19 March 2021 worth over $226,000. On average, Alan trades about 1,586 units every 149 days since 2015. As of 1 May 2024 he still owns at least 23,794 units of Vericel Corp stock.
You can see the complete history of Mr. Rubino stock trades at the bottom of the page.
Alan L. Rubino is an Independent Director of the company. Prior to joining Emisphere, Mr. Rubino is a director since September 2005, has served as President and Chief Executive Officer of RenovaCare, Inc., a publicly-held biotechnology company, since November 2019. Prior to RenovaCare, from September 2012 to November 2019, Mr. Rubino served as Chief Executive Officer and President of Emisphere Technologies, Inc., a publicly-held company. Prior to joining Emisphere, Mr. Rubino served as Chief Executive Officer and President of New American Therapeutics, Inc., a specialty pharmaceutical company, from October 2010 to August 2012, where he led the acquisition of penciclovir from Novartis AG. From February 2008 to September 2010, Mr. Rubino served as the Chief Executive Officer and President of Akrimax Pharmaceuticals, LLC, an integrated specialty pharmaceutical company. Prior to this, he served as President and Chief Operating Officer of Pharmos Corporation, a biopharmaceutical company. Mr. Rubino has continued to expand upon a highly successful and distinguished career that included Hoffmann-La Roche, Inc., a research-focused healthcare company, from 1977 to 2001, where he was a member of the U.S. Executive and Operating Committees and an executive officer. During his Hoffman-La Roche tenure, he held a series of key executive positions in marketing, sales, business operations, supply chain and human resource management. In addition, he was assigned to various executive committee roles in the areas of marketing, project management, and globalization of Roche Holdings. Mr. Rubino also held senior executive positions at PDI, Inc., a sales and marketing support company, and Cardinal Health, a company focused on improving the cost-effectiveness of health care, from 2001 to 2003. He received a Bachelor of Arts degree in economics from Rutgers University with a minor in biology/chemistry and also completed post-graduate educational programs at the University of Lausanne and Harvard Business School.
As the Independent Director of Vericel Corp, the total compensation of Alan Rubino at Vericel Corp is $237,585. There are 8 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
Alan Rubino is 65, he's been the Independent Director of Vericel Corp since 2005. There are 2 older and 12 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
Alan's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel и Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Vericel Corp executives and other stock owners filed with the SEC include: